CN106488931B - 抗hsv抗体的局部应用 - Google Patents

抗hsv抗体的局部应用 Download PDF

Info

Publication number
CN106488931B
CN106488931B CN201580034015.2A CN201580034015A CN106488931B CN 106488931 B CN106488931 B CN 106488931B CN 201580034015 A CN201580034015 A CN 201580034015A CN 106488931 B CN106488931 B CN 106488931B
Authority
CN
China
Prior art keywords
ala
hsv
val
thr
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580034015.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN106488931A (zh
Inventor
M·安德特
J·卡乌斯
D·耶格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Priority to CN202210007608.1A priority Critical patent/CN114306596A/zh
Publication of CN106488931A publication Critical patent/CN106488931A/zh
Application granted granted Critical
Publication of CN106488931B publication Critical patent/CN106488931B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580034015.2A 2014-06-26 2015-06-25 抗hsv抗体的局部应用 Active CN106488931B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210007608.1A CN114306596A (zh) 2014-06-26 2015-06-25 抗hsv抗体的局部应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14174174.4 2014-06-26
EP14174174 2014-06-26
PCT/EP2015/064378 WO2015197763A1 (en) 2014-06-26 2015-06-25 Topical application for an anti-hsv antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210007608.1A Division CN114306596A (zh) 2014-06-26 2015-06-25 抗hsv抗体的局部应用

Publications (2)

Publication Number Publication Date
CN106488931A CN106488931A (zh) 2017-03-08
CN106488931B true CN106488931B (zh) 2021-12-28

Family

ID=51032986

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580034015.2A Active CN106488931B (zh) 2014-06-26 2015-06-25 抗hsv抗体的局部应用
CN202210007608.1A Pending CN114306596A (zh) 2014-06-26 2015-06-25 抗hsv抗体的局部应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210007608.1A Pending CN114306596A (zh) 2014-06-26 2015-06-25 抗hsv抗体的局部应用

Country Status (13)

Country Link
US (2) US11267871B2 (https=)
EP (1) EP3160997B1 (https=)
JP (1) JP6649284B2 (https=)
KR (1) KR102622280B1 (https=)
CN (2) CN106488931B (https=)
AU (1) AU2015279212B2 (https=)
CA (1) CA2950489C (https=)
ES (1) ES2843277T3 (https=)
NZ (1) NZ726168A (https=)
RU (1) RU2703903C2 (https=)
SG (1) SG11201610320RA (https=)
WO (1) WO2015197763A1 (https=)
ZA (1) ZA201607813B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3055555A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgf.beta.1-binding immunoglobulins and use thereof
EP3566749A4 (en) * 2017-01-09 2020-09-23 Medshine Discovery Inc. THIAZOLE DERIVATIVE AND USES OF IT
US11472867B2 (en) 2017-08-30 2022-10-18 Km Biologics Co., Ltd. Anti-HSV GB monoclonal antibody or antigen-binding fragment thereof
US12247066B2 (en) 2018-08-28 2025-03-11 Pontificia Universídad Católica de Chile Monoclonal antibody 14F5F6 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2
WO2020041911A1 (es) * 2018-08-28 2020-03-05 Pontificia Universidad Catolica De Chile Anticuerpo monoclonal 11b2c7 o fragmento del mismo, que reconoce específicamente virus herpes simple 1 y 2
EP3941524A1 (en) * 2019-03-19 2022-01-26 Albert Einstein College of Medicine Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
WO2022002802A1 (en) * 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa HSV gEgI HETERODIMER ANTIBODIES
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20260001939A1 (en) * 2022-03-02 2026-01-01 Heidelberg Immunotherapeutics Gmbh Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
TW202426053A (zh) * 2022-09-02 2024-07-01 聯合生物製藥股份有限公司 單純皰疹病毒感染的治療
EP4727967A1 (en) 2023-06-16 2026-04-22 Heidelberg ImmunoTherapeutics GmbH Novel anti-hsv antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156313A (en) * 1994-01-04 2000-12-05 The Scripps Research Institute Human monoclonal antibodies to herpes simplex virus and methods therefor
WO2010128053A1 (en) * 2009-05-04 2010-11-11 Ribovax Biotechnologies Sa Antigen binding fragments of an antibody for use in treating or diagnosing ocular diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1222281B1 (en) * 1999-09-30 2006-11-15 University of Washington Immunoligically significant herpes simplex virus antigens
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US20070274997A1 (en) 2003-07-25 2007-11-29 Anthony Simmons Compositions and Methods for Herpes Simplex Prophylaxis and Treatment
US6984492B2 (en) * 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
WO2010129033A2 (en) 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
EP2308895A1 (en) * 2009-10-01 2011-04-13 Universität Duisburg-Essen Anti-HSV antibody
EP2694542A4 (en) * 2011-04-08 2014-10-08 Univ Duke HERPES SIMPLEX VIRUS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156313A (en) * 1994-01-04 2000-12-05 The Scripps Research Institute Human monoclonal antibodies to herpes simplex virus and methods therefor
WO2010128053A1 (en) * 2009-05-04 2010-11-11 Ribovax Biotechnologies Sa Antigen binding fragments of an antibody for use in treating or diagnosing ocular diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes;Jill Sherwood等;《Nature Biotechnology》;19960414;第468-471页 *

Also Published As

Publication number Publication date
RU2017102387A (ru) 2018-07-26
US20220169705A1 (en) 2022-06-02
EP3160997A1 (en) 2017-05-03
JP6649284B2 (ja) 2020-02-19
RU2017102387A3 (https=) 2018-07-26
WO2015197763A1 (en) 2015-12-30
EP3160997B1 (en) 2020-10-28
CN106488931A (zh) 2017-03-08
JP2017520572A (ja) 2017-07-27
KR102622280B1 (ko) 2024-01-08
ES2843277T3 (es) 2021-07-16
AU2015279212A2 (en) 2017-04-27
CA2950489C (en) 2022-09-20
NZ726168A (en) 2022-05-27
CN114306596A (zh) 2022-04-12
AU2015279212A1 (en) 2016-12-01
RU2703903C2 (ru) 2019-10-22
BR112016030422A2 (pt) 2017-10-24
CA2950489A1 (en) 2015-12-30
AU2015279212B2 (en) 2020-08-20
US11267871B2 (en) 2022-03-08
US20170152304A1 (en) 2017-06-01
SG11201610320RA (en) 2017-01-27
KR20170020423A (ko) 2017-02-22
ZA201607813B (en) 2018-05-30

Similar Documents

Publication Publication Date Title
US20220169705A1 (en) Topical application for an anti-hsv antibody
US9657088B2 (en) Anti-HSV antibody
Krawczyk et al. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus
WO2019044926A1 (ja) 抗ＨＳＶ ｇＢモノクローナル抗体又はその抗原結合断片
TWI402076B (zh) 抗介白素－２０抗體用於製造治療中風的醫藥組合物之用途
CN108472372B (zh) 结合不动杆菌的抗体结合剂及其用途
Jose et al. A cationic peptide, TAT-Cd0, inhibits herpes simplex virus type 1 ocular infection in vivo
TWI695720B (zh) 藉由針對ｃｄ４之單株抗體調停競爭型ｈｉｖ進入抑制之ｈｉｖ感染的治療和功能性治癒
Gill et al. Biologic drug development for treatment and prevention of sexually transmitted infections
AU2019252565B2 (en) Methods and compositions for treating yellow fever
BR112016030422B1 (pt) Anticorpo anti-hsv e composição farmacêutica compreendendo o referido anticorpo
EP4727967A1 (en) Novel anti-hsv antibody
US9944693B2 (en) HIV antigens and antibodies and compositions, uses and methods thereof
WO2025250861A1 (en) Broadly neutralizing anti-hcmv antibodies and uses thereof
CN119997976A (zh) 单纯疱疹病毒感染的治疗
CN119326878A (zh) 抗IL-4Rα抗体治疗慢性鼻窦炎的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant